Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology
- Sylvia Hartmann1Email author,
- Mine Eray2,
- Claudia Döring1,
- Tuula Lehtinen3,
- Uta Brunnberg4,
- Paula Kujala2,
- Martine Vornanen†2 and
- Martin-Leo Hansmann†1
© Hartmann et al.; licensee BioMed Central Ltd. 2014
Received: 2 March 2014
Accepted: 9 May 2014
Published: 13 May 2014
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) usually presents in middle aged men and shows an indolent clinical behavior. However, up to 30% of the patients present a secondary transformation into aggressive diffuse large B cell lymphoma (DLBCL). The aim of the present study was to characterize morphology and immunophenotype of this kind of DLBCL in detail and compare it with conventional DLBCL.
Morphology and immunophenotype of 33 cases of NLPHL with simultaneous or sequential transformation into DLBCL were investigated. These cases were compared with 41 de novo DLBCL in Finnish men.
The majority of cases exhibited different immunophenotypes in the NLPHL and the DLBCL components. The immunophenotype of the DLBCL secondary to NLPHL was heterogeneous. However, BCL6, EMA, CD75 and J-chain were usually expressed in both components (≥73% positive). Overall, the NLPHL component was more frequently positive for EMA, CD75 and J-chain than the DLBCL component. In contrast, B cell markers, CD10 and BCL2, were more frequently expressed and were expressed at higher levels in the DLBCL component than in the NLPHL component. In the independent series of de novo DLBCL 4 cases could be identified with a growth pattern and immunophenotype that suggested that they had arisen secondarily from NLPHL.
The morphology and immunophenotype of DLBCL arisen from NLPHL is heterogeneous. Further characterization of the particular molecular features of this subgroup is warranted to be able to better identify these cases among conventional DLBCL.
KeywordsNodular lymphocyte predominant Hodgkin lymphoma Diffuse large B cell lymphoma Transformation
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma (HL), which accounts for approximately 5% of all cases  and generally presents with early clinical stages and an indolent clinical behavior [2, 3]. Middle aged males account for 75% of cases . Histologically, NLPHL typically consists of large nodules of reactive small B cells with a few intermingled tumor cells, the so called lymphocyte predominant or LP cells. Morphologic variants with a diffuse pattern or an abundant reactive T cell infiltrate mimicking T cell/histiocyte rich B cell lymphoma (THRLBCL) have been described [4, 5]. Gene expression profiling studies have identified only marginal differences between LP cells and tumor cells of THRLBCL [6, 7]. In contrast to Hodgkin and Reed-Sternberg cells of classical HL, LP cells usually show a preserved or only partially downregulated B cell phenotype [6, 8]. They typically exhibit constitutive NF-kappaB activity  and active JAK-STAT-signaling . Recently, germline mutations of the NPAT gene have been identified as risk factor for NLPHL in the Finnish population  and there are reports about a high familial risk in first degree relatives of NLPHL patients [11, 12].
In the past 20 years, simultaneous or secondary transformation of NLPHL into diffuse large B cell lymphoma (DLBCL) has been described in up to 30% of cases [13–18]. Several studies have suggested that these patients have a favorable outcome [13, 14, 16, 17, 19]. However, one study did not confirm this observation . The male: female ratio for cases of NLPHL transformed into DLBCL was slightly higher than for primary NLPHL (77 - 81%) [14–17]. The aim of the present study was to characterize morphology and immunophenotype of DLBCL simultaneously or sequentially derived from NLPHL in 33 cases. A second aim was the comparison of the immunophenotype observed in these particular cases with conventional DLBCL, in order to identify a marker panel, which allows to detect DLBCL, representing a putative transformation from NLPHL, in an independent series of DLBCL.
A series of 33 consecutive cases of composite lymphoma of NLPHL and DLBCL were identified from the archives of the Dr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany and the Department of Pathology, Tampere University Hospital, Tampere, Finland. Original diagnoses were made between 1987 and 2013. Original slides were complemented by additional stainings (see below). All diagnoses could be confirmed according to the WHO classification 2008 after joint review (S.H., M.E., M.V. and in part M.L.H.). In 26 cases both the NLPHL and DLBCL were present in the same biopsy, and in 7 cases, the DLBCL occurred sequentially after NLPHL. Two patients with simultaneous presentation of NLPHL and DLBCL had a previous history of NLPHL. NLPHL cases with transformation into pure THRLBCL were not included in the present study, since different mechanisms of transformation may be involved in these cases.
In a second step, 41 consecutive cases of male patients with DLBCL, diagnosed at the Pathology Department of Tampere University between 2003 and 2010, were selected from the archives and analyzed to identify cases representing a transformation from NLPHL (“LP-type DLBCL”).
The study was approved by the local ethics committees of Frankfurt and Tampere University Hospital (ethics votes 120/13 from May, 23rd 2013 and 7085/05.01.00.06/2010 from October, 5th 2010).
All composite cases of NLPHL and DLBCL were investigated for CD20, CD79a, CD19, CD3, EMA, J-chain, CD75, CD10, BCL2, BCL6, CD30, CD15, MUM1, IgD, p-STAT6, JAK2 and EBER.
The cases of the second series of DLBCL were stained for CD20, CD3, CD10, BCL6, BCL2, CD75, EMA, J-chain and MUM1. In cases where transformation from NLPHL seemed likely, the specimens were additionally studied for IgD, CD30, CD15, and EBER. Twenty-eight cases each of DLBCL derived from NLPHL and conventional DLBCL were evaluated for the presence of follicular dendritic cells (FDCs) by CD21 and CD23.
Immunostainings were performed in the Pathology departments of Frankfurt and Tampere University using either an Alkaline Phosphatase-Real Detection Kit (DAKO, Glostrup, Denmark) or Peroxidase-EnVision Plus Kit (DAKO) as described previously . The antibodies used, dilutions, and providers are listed in Additional file 1: Table S1. Antigen unmasking was performed for 3 min in a pressure cooker in TRIS-EDTA pH 8.0. All stainings were assessed using a multi-head microscope, and were scored as positive or weakly positive if > 50% of the tumor cells showed a reaction with the respective antibodies. Positivity perceivable at low magnification (4×) was scored strongly positive, positivity only noticeable at higher magnification was scored weakly positive. Intensity of B cell markers (CD20, CD79a, CD19) was scored weakly positive if the expression intensity was weaker than in small reactive B cells. In the composite cases it was also assessed, if the tumor cells in the DLBCL component showed enhanced or attenuated expression compared with the LP cells in the NLPHL component.
Clinical and morphologic findings of NLPHL + DLBCL composite lymphomas
Clinical characteristics of patients studied
NLPHL-DLBCL (n = 33)
Conventional DLBCL (n = 41)
Patients with simultaneous involvement by NLPHL and DLBCL
Patients with sequential involvement by NLPHL and DLBCL
Median patient age (range)
50 (19– 78)
69 (19– 93)
male gender (%)
- cervical/ supraclavicular
- abdominal/ mesenteric LN /bowel
- mediastinal/ retroperitoneal
Morphologic findings of NLPHL + DLBCL composite lymphomas
Immunophenotype of NLPHL + DLBCL composite lymphomas
Immunophenotype of composite lymphomas with NLPHL and DLBCL
DLBCL component positive
LP cells positive
Reduced expression in DLBCL component
Enhanced expression in DLBCL component
Identical expression in DLBCL and NLPHL component
Identical expression in DLBCL and NLPHL in simultaneous cases
Independent series of conventional DLBCL
In order to compare DLBCL transformed from NLPHL (“LP type” DLBCL) with conventional DLBCL and to identify more cases that may be derived from NLPHL, we evaluated an independent series of 41 DLBCL for their morphology and immunophenotype. Because of the high prevalence of males in the first series, we decided to investigate all males diagnosed with DLBCL at the Pathology Department of Tampere between 2003 and 2013. Clinical data are shown in Table 1. Because we had observed typical positivity for BCL6, CD75, EMA, J-chain, and weak MUM1 expression as well as negativity or weak positivity for BCL2 in “LP type” DLBCL, all cases of the second series were stained for theses antigens and were additionally evaluated for the presence of FDCs.
Immunophenotype of “LP type” DLBCL (transformed from NLPHL) compared to conventional DLBCL
Staining pattern typically observed in DLBCL transformed from NLPHL
“LP type” DLBCL (n = 33)
Conventional DLBCL (n = 41)
Bcl-6 strongly positive
CD10 weakly or strongly positive
CD75 weakly or strongly positive
EMA weakly or strongly positive
MUM1 weakly or strongly positive
J-chain weakly or strongly positive
Bcl2 weakly positive or negative
CD21-positive follicular dendritic cells
CD23-positive follicular dendritic cells
Clinical features of four DLBCL cases with putative derivation from NLPHL
The median age of these patients was 31.5 years. The localization of the biopsies were cervical (in two cases), axillary and mesenteric. One patient was diagnosed in stage II, one in stage III, and two in stage IV. Three of four patients presented splenic involvement, and two of these additionally presented liver involvement. Two patients achieved complete remission after R-CHOP/R-CHOEP, and one patient achieved remission after R-CHOP and subsequent autologous stem cell transplant. One patient received DHAP but died few months after diagnosis.
In the present study we investigated 33 patients with NLPHL and transformation into DLBCL. Although 26 of 33 patients in the present study showed a simultaneous presentation of NLPHL and DLBCL, the clinical data match well with previous studies of secondary transformations of NLPHL into DLBCL [16, 17]. Histopathologic variant patterns (“Non-A/B”) as described by Fan et al.  were seen in the NLPHL component in 70% of composite cases investigated in the present study. Histopathologic variants have been associated with advanced stage and an increased risk of relapse [4, 5, 22] and the high frequency in the present study likely points to an increased risk of transformation into DLBCL in these patients.
In the present study, we observed in most composite NLPHL-DLBCL cases, a particular pattern of infiltration with a sharply demarcated sheet-like blast expansion or with a relatively high number of histiocytes admixed with the DLBCL component. The morphology of the nuclei was variable, as previously observed . The most common immunophenotype, differing from conventional DLBCL, was coexpression of EMA and J-chain. However, this immunophenotype was not specific. EMA expression in DLBCL derived from NLPHL was also observed in one previous study . Another remarkable observation was the upregulation of B cell markers as well as BCL2 in the DLBCL component compared to the NLPHL component. Possibly, the slight downregulation of B cell receptor signaling observed in the LP cells of NLPHL [6, 8] is substituted by stimulation from rosetting follicular T helper cells. Since T cell rosetting was never observed in the DLBCL component, these tumor cells must have acquired additional properties to ensure their survival. One of these features may represent enhanced tonic active B cell receptor signaling [23–25] or the upregulation of BCL2 anti-apoptotic protein [26, 27]. The increased number of tumor cells in “LP type” DLBCL compared to the NLPHL component may result from enhanced anti-apoptotic properties resulting from BCL2 expression. In the present series, p-STAT6 and JAK2 were expressed in both components less frequently than previously observed . Possibly, SOCS1-mutated NLPHL cases with active JAK-STAT-signaling are less likely to transform into DLBCL and may, therefore, have a better prognosis similar to DLBCL with truncating SOCS1 mutations . We also observed upregulation of CD15 and CD10 in some cases of “LP type” DLBCL. CD15 expression has been described in a subset of NLPHL-DLBCL composite lymphomas , whereas CD15 expression in NLPHL generally is a rare phenomenon [3, 29, 30]. Upregulation of these markers may be associated with activation of the tumor cells as observed for CD30 expression [31–33].
Since we also identified four cases with a typical “LP type” infiltration pattern and immunophenotype in a series of conventional DLBCL, we hypothesize that a series of conventional DLBCL cases will include cases with transformation from NLPHL, particularly if diagnoses are made on small core biopsies. Since some of the composite cases showed a downregulation of J-chain and EMA as well as an upregulation of CD10 and BCL2 in the DLBCL component, these cases may be difficult to identify applying current histopathologic methods if only the DLBCL component is sampled. Furthermore, the immunohistochemical stainings, observed to be frequently positive in the present study, were not specific, as was demonstrated in the case of transformed marginal zone lymphoma, which was positive for both EMA and J-chain.
In the present study we observed a heterogeneous immunophenotype of DLBCL derived from NLPHL, which may reflect different mechanisms of transformation. This fact makes these cases difficult to recognize, if the NLPHL component is not sampled. Men with sharply demarcated blast infiltrates with EMA- and/or J-chain expression and abdominal, splenic, or axillary localization are more likely to have “LP type” DLBCL. However, it is important to state, that by applying current immunohistochemical markers, there is no way to specifically recognize these cases unless the coexisting NLPHL component can be identified. Therefore, further characterization of the particular clinical and molecular features of “LP type” DLBCL among conventional DLBCL is warranted, and may lead to identification of better diagnostic markers.
The authors thank Prof. Timo Paavonen and the University of Tampere for providing facilities and materials essential for this study. We thank Yvonne Michel, Ralf Lieberz, and Sabine Albrecht for excellent technical assistance. The authors thank Prof. Ralf Küppers, Essen, for helpful discussions. This project was funded by the Deutsche Forschungsgemeinschaft (DFG) grant HA 6145/1-1.
- Swerdlow SH: International Agency for Research on Cancer. World Health Organization: WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. 2008, Lyon, France: International Agency for Research on CancerGoogle Scholar
- Sextro M, Diehl V, Franklin J, Hansmann ML, Anagnostopoulos I, Marafioti T, Stein H: Lymphocyte predominant Hodgkin's disease--a workshop report. European Task Force on Lymphoma. Ann Oncol. 1996, 4 (7 Suppl): 61-65.View ArticleGoogle Scholar
- Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, Van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H: European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000, 96 (5): 1889-1899.PubMedGoogle Scholar
- Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA: Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003, 27 (10): 1346-1356. 10.1097/00000478-200310000-00007.View ArticlePubMedGoogle Scholar
- Boudova L, Torlakovic E, Delabie J, Reimer P, Pfistner B, Wiedenmann S, Diehl V, Muller-Hermelink HK, Rudiger T: Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003, 102 (10): 3753-3758. 10.1182/blood-2003-02-0626.View ArticlePubMedGoogle Scholar
- Brune V, Tiacci E, Pfeil I, Doring C, Eckerle S, Van Noesel CJ, Klapper W, Falini B, Von Heydebreck A, Metzler D, Brauninger A, Hansmann ML, Kuppers R: Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008, 205 (10): 2251-2268. 10.1084/jem.20080809.View ArticlePubMedPubMed CentralGoogle Scholar
- Hartmann S, Doring C, Jakobus C, Rengstl B, Newrzela S, Tousseyn T, Sagaert X, Ponzoni M, Facchetti F, De Wolf-Peeters C, Steidl C, Gascoyne R, Kuppers R, Hansmann ML: Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - endpoints of a spectrum of one disease?. PLoS One. 2013, 8 (11): e78812-10.1371/journal.pone.0078812.View ArticlePubMedPubMed CentralGoogle Scholar
- Tedoldi S, Mottok A, Ying J, Paterson JC, Cui Y, Facchetti F, Van Krieken JH, Ponzoni M, Ozkal S, Masir N, Natkunam Y, Pileri S, Hansmann ML, Mason D, Tao Q, Marafioti T: Selective loss of B-cell phenotype in lymphocyte predominant Hodgkin lymphoma. J Pathol. 2007, 213 (4): 429-440. 10.1002/path.2242.View ArticlePubMedGoogle Scholar
- Mottok A, Renne C, Willenbrock K, Hansmann ML, Brauninger A: Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood. 2007, 110 (9): 3387-3390. 10.1182/blood-2007-03-082511.View ArticlePubMedGoogle Scholar
- Saarinen S, Aavikko M, Aittomaki K, Launonen V, Lehtonen R, Franssila K, Lehtonen HJ, Kaasinen E, Broderick P, Tarkkanen J, Bain BJ, Bauduer F, Unal A, Swerdlow AJ, Cooke R, Makinen MJ, Houlston R, Vahteristo P, Aaltonen LA: Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma. Blood. 2011, 118 (3): 493-498. 10.1182/blood-2011-03-341560.View ArticlePubMedGoogle Scholar
- Saarinen S, Pukkala E, Vahteristo P, Makinen MJ, Franssila K, Aaltonen LA: High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2013, 31 (7): 938-943. 10.1200/JCO.2012.43.5958.View ArticlePubMedGoogle Scholar
- Merli M, Maffioli M, Ferrario A, Passamonti F: Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma. Am J Hematol. 2013, 88 (8): 719-720.View ArticlePubMedGoogle Scholar
- Sundeen JT, Cossman J, Jaffe ES: Lymphocyte predominant Hodgkin's disease nodular subtype with coexistent "large cell lymphoma". Histological progression or composite malignancy?. Am J Surg Pathol. 1988, 12 (8): 599-606.PubMedGoogle Scholar
- Hansmann ML, Stein H, Fellbaum C, Hui PK, Parwaresch MR, Lennert K: Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol. 1989, 20 (12): 1169-1175. 10.1016/S0046-8177(89)80007-3.View ArticlePubMedGoogle Scholar
- Huang JZ, Weisenburger DD, Vose JM, Greiner TC, Aoun P, Chan WC, Lynch JC, Bierman PJ, Armitage JO: Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma. 2004, 45 (8): 1551-1557. 10.1080/1042819031000149421.View ArticlePubMedGoogle Scholar
- Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ: Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol. 2010, 28 (5): 793-799. 10.1200/JCO.2009.24.9516.View ArticlePubMedGoogle Scholar
- Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Divine M, Brice P: Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2010, 116 (3): 631-639. 10.1002/cncr.24819.View ArticlePubMedGoogle Scholar
- Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A: Lymphocyte-predominant Hodgkin lymphoma–clinical features and treatment outcomes from a 30-year experience. Ann Oncol. 2010, 21 (10): 2061-2068. 10.1093/annonc/mdq063.View ArticlePubMedGoogle Scholar
- Cotta CV, Coleman JF, Li S, Hsi ED: Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site. Histopathology. 2011, 59 (6): 1194-1203. 10.1111/j.1365-2559.2011.04054.x.View ArticlePubMedGoogle Scholar
- Renné C, Willenbrock K, Küppers R, Hansmann ML, Bräuninger A: Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood. 2005, 105 (10): 4051-4059. 10.1182/blood-2004-10-4008.View ArticlePubMedGoogle Scholar
- Ochiai K, Maienschein-Cline M, Simonetti G, Chen J, Rosenthal R, Brink R, Chong AS, Klein U, Dinner AR, Singh H, Sciammas R: Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of IRF4. Immunity. 2013, 38 (5): 918-929. 10.1016/j.immuni.2013.04.009.View ArticlePubMedPubMed CentralGoogle Scholar
- Hartmann S, Eichenauer DA, Plutschow A, Mottok A, Bob R, Koch K, Bernd HW, Cogliatti S, Hummel M, Feller AC, Ott G, Moller P, Rosenwald A, Stein H, Hansmann ML, Engert A, Klapper W: The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013, 122 (26): 4246-4252. 10.1182/blood-2013-07-515825.View ArticlePubMedGoogle Scholar
- Lam KP, Kühn R, Rajewsky K: In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997, 90: 1073-1083. 10.1016/S0092-8674(00)80373-6.View ArticlePubMedGoogle Scholar
- Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K: Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004, 117: 787-800. 10.1016/j.cell.2004.05.014.View ArticlePubMedGoogle Scholar
- Young RM, Staudt LM: Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013, 12 (3): 229-243. 10.1038/nrd3937.View ArticlePubMedGoogle Scholar
- Alnemri ES, Robertson NM, Fernandes TF, Croce CM, Litwack G: Overexpressed full-length human BCL2 extends the survival of baculovirus-infected Sf9 insect cells. Proc Natl Acad Sci U S A. 1992, 89 (16): 7295-7299. 10.1073/pnas.89.16.7295.View ArticlePubMedPubMed CentralGoogle Scholar
- Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A. 1991, 88 (16): 6961-6965. 10.1073/pnas.88.16.6961.View ArticlePubMedPubMed CentralGoogle Scholar
- Schif B, Lennerz JK, Kohler CW, Bentink S, Kreuz M, Melzner I, Ritz O, Trumper L, Loeffler M, Spang R, Moller P: SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients. Oncotarget. 2013, 4 (1): 35-47.PubMedGoogle Scholar
- Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES: CD15-expressing nodular lymphocyte-predominant Hodgkin lymphoma. Histopathology. 2011, 58 (5): 803-805. 10.1111/j.1365-2559.2011.03829.x.View ArticlePubMedGoogle Scholar
- Huppmann AR, Nicolae A, Slack GW, Pittaluga S, Davies-Hill T, Ferry JA, Harris NL, Jaffe ES, Hasserjian RP: EBV May Be Expressed in the LP Cells of Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) in Both Children and Adults. Am J Surg Pathol. 2014, 38 (3): 316-324. 10.1097/PAS.0000000000000107.View ArticlePubMedPubMed CentralGoogle Scholar
- Segal GH, Kjeldsberg CR, Smith GP, Perkins SL: CD30 antigen expression in florid immunoblastic proliferations. A clinicopathologic study of 14 cases. Am J Clin Pathol. 1994, 102 (3): 292-298.View ArticlePubMedGoogle Scholar
- Engels EA, Savoldo B, Pfeiffer RM, Costello R, Zingone A, Heslop HE, Landgren O: Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation. 2013, 95 (3): 519-526. 10.1097/TP.0b013e318274ab63.View ArticlePubMedPubMed CentralGoogle Scholar
- Guo Y, Sun X, Shibata K, Yamada H, Muta H, Podack ER, Yoshikai Y: CD30 is required for activation of a unique subset of interleukin-17A-producing gammadelta T cells in innate immunity against Mycobacterium bovis Bacillus Calmette-Guerin infection. Infect Immun. 2013, 81 (10): 3923-3934. 10.1128/IAI.00887-13.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/332/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.